Journal article
Additive Effects of Cu-ATSM and Radiation on Survival of Diffuse Intrinsic Pontine Glioma Cells
Radiation research, Vol.203(1), pp.10-17
01/2025
DOI: 10.1667/RADE-24-00076.1
PMCID: PMC11815956
PMID: 39492578
Abstract
Diffuse intrinsic pontine gliomas (DIPG) are highly aggressive and treatment-resistant childhood primary brainstem tumors with a median survival of less than one year after diagnosis. The prevailing standard of care for DIPG, radiation therapy, does not prevent fatal disease progression, with most patients succumbing to this disease 3-8 months after completion of radiation therapy. This underscores the urgent need for novel combined-modality approaches for enhancing therapy responses. This study demonstrates that the cellular redox modulating drug, copper (II)-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM) dose-dependently (1-3 μM) decreased clonogenic cell survival in SU-DIPG50 and SU-DIPG36 cell lines during 6 h of exposure but had no significant effect on survival in normal human astrocytes (NHA). Additional significant (>90%) decreases in DIPG clonogenic survival were observed at 24 h of Cu-ATSM exposure. However, NHAs also began to show dose-dependent 10-70% survival decreases at this point. Notably, 3 μM Cu-ATSM for 6 h resulted in additive clonogenic cell killing of DIPG lines when combined with radiation, which was not seen in NHAs and was partially inhibited by the copper chelator, bathocuproinedisulfonic acid. Cu-ATSM toxicity in DIPG cells was also inhibited by overexpression of mitochondrial-targeted catalase. These results support the hypothesis that Cu-ATSM is selectively cytotoxic to DIPGs by a mechanism involving H2O2 generation and copper and being additively cytotoxic with ionizing radiation.Diffuse intrinsic pontine gliomas (DIPG) are highly aggressive and treatment-resistant childhood primary brainstem tumors with a median survival of less than one year after diagnosis. The prevailing standard of care for DIPG, radiation therapy, does not prevent fatal disease progression, with most patients succumbing to this disease 3-8 months after completion of radiation therapy. This underscores the urgent need for novel combined-modality approaches for enhancing therapy responses. This study demonstrates that the cellular redox modulating drug, copper (II)-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM) dose-dependently (1-3 μM) decreased clonogenic cell survival in SU-DIPG50 and SU-DIPG36 cell lines during 6 h of exposure but had no significant effect on survival in normal human astrocytes (NHA). Additional significant (>90%) decreases in DIPG clonogenic survival were observed at 24 h of Cu-ATSM exposure. However, NHAs also began to show dose-dependent 10-70% survival decreases at this point. Notably, 3 μM Cu-ATSM for 6 h resulted in additive clonogenic cell killing of DIPG lines when combined with radiation, which was not seen in NHAs and was partially inhibited by the copper chelator, bathocuproinedisulfonic acid. Cu-ATSM toxicity in DIPG cells was also inhibited by overexpression of mitochondrial-targeted catalase. These results support the hypothesis that Cu-ATSM is selectively cytotoxic to DIPGs by a mechanism involving H2O2 generation and copper and being additively cytotoxic with ionizing radiation.
Details
- Title: Subtitle
- Additive Effects of Cu-ATSM and Radiation on Survival of Diffuse Intrinsic Pontine Glioma Cells
- Creators
- Sarah A King - University of IowaShane R Solst - University of IowaClaire H Graham - University of IowaLianna Z Fiore - University of IowaRana Rheem - University of IowaAnn Tomanek-Chalkley - University of IowaMelissa A Fath - University of IowaJoseph M Caster - University of IowaDouglas R Spitz - University of IowaMichelle E Howard - University of Iowa
- Resource Type
- Journal article
- Publication Details
- Radiation research, Vol.203(1), pp.10-17
- DOI
- 10.1667/RADE-24-00076.1
- PMID
- 39492578
- PMCID
- PMC11815956
- NLM abbreviation
- Radiat Res
- ISSN
- 1938-5404
- eISSN
- 1938-5404
- Publisher
- Radiation Research Society
- Grant note
- National Center for Advancing Translational Sciences of the National Institutes of Health: P01CA2177 97, P01 CA244091, R50 CA243693, P30 CA086862, K12TR004382 Pediatric Brain Tumor Research Fund at The University of Iowa
The authors thank the Radiation and Free Radical Research Core and the Flow cytometry Core Facilities for technical support. Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number K12TR004382 (MEH) , P01CA2177 97 (DRS, ATC) , P01 CA244091 (DRS) , R50 CA243693 (MAF) , P30 CA086862 (DRS) . The content is solely the author's responsibility and does not necessarily represent the official views of the National Institutes of Health. Funding for this work was also provided by the Pediatric Brain Tumor Research Fund at The University of Iowa, including funds from Research for the Kids and Rally for Reid foundations.
- Language
- English
- Electronic publication date
- 11/04/2024
- Date published
- 01/2025
- Academic Unit
- Pathology; Iowa Neuroscience Institute; Radiation Oncology; Fraternal Order of Eagles Diabetes Research Center
- Record Identifier
- 9984742559502771
Metrics
15 Record Views